Because adult worms are long lived and fecund for most of their lifespan, populations in endemic regions must be treated for many years. Suboptimal responders are observed, indicating possible resistance development. Further, severe adverse effects may develop.
A promising approach is to target the Wolbachia using doxycycline or rifampicin. However, an impediment to their use is the contraindication for children and possible formation of resistance, respectively. Rifampicin is given as a standard drug against tuberculosis. Thus, there is a clear benefit by avoiding the use of rifampicin for other indications to minimize the risk of developing resistance in M. tuberculosis. CorA is a beneficial alternative to rifampicin for treating filariasis.
On behalf of the University of Bonn, PROvendis offers an access to rights for commercial use of this invention and the opportunity for further co-development.
An EP and an US patent application have been filed.
Data of in vitro and in vivo experiments are available.
A. Schiefer et al. (2012), JID, 206:249-57
A. Hoerauf et al. (2011), CMI, 17:977-85